In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

High-dose statin therapy is effective at preventing the development of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a meta-analy

Session PCI complications

Speaker Evangelos Oikonomou

Event : ESC Congress 2016

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Coronary Intervention: Complications
  • Session type : Moderated Posters

Authors : T Zografos (Athens,GR), E Oikonomou (Athens,GR), G Siasos (Athens,GR), K Mourouzis (Athens,GR), A Antonopoulos (Athens,GR), M Vavuranakis (Athens,GR), S Tsalamandris (Athens,GR), D Tousoulis (Athens,GR)

Authors:
T. Zografos1 , E. Oikonomou1 , G. Siasos1 , K. Mourouzis1 , A. Antonopoulos1 , M. Vavuranakis1 , S. Tsalamandris1 , D. Tousoulis1 , 1Hippokration General Hospital, 1st Cardiology Department - Athens - Greece ,

Citation:
European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 612-613

Background: Contrast-induced nephropathy (CIN) is often encountered following percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) and is associated with high in-hospital morbidity and mortality. Statins may prevent the development of CIN, however their efficacy in patients with ACS has not been evaluated.

Purpose: We conducted a meta-analysis of randomized controlled trials (RCTs) to assess statin efficacy in the prevention of CIN in patients undergoing PCI for ACS.

Methods: PubMed, EMBASE, MEDLINE and the Cochrane Central Register were searched for RCTs from inception to September 2014 to compare high-dose statins (rosuvastatin 40mg/day, atorvastatin 80mg/day or simvastatin 80mg/day) with low-dose statins (atorvastatin 10mg/day, simvastatin 10mg/day) or placebo treatment in patients with ACS, undergoing PCI. Study-specific odds ratios (ORs) were calculated, and between-study heterogeneity was assessed using the I2 statistic. We used a random effects model meta-analysis to pool the OR.

Results: Seven RCTs, including 5174 patients were included in the analysis. CIN occurred in 126 (4.9 patients in the high dose statin group and in 232 (8.9%) patients in the low dose or placebo group (OR: 0.50, 95% confidence interval: 0.38- 0.66, p<0.001). The observed heterogeneity between the included studies was low (I2=19%, p=0.28).

Conclusions: High-dose statin therapy is effective at preventing the development of CIN in the high-risk population of patients undergoing PCI for ACS.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are